Lifecore Biomedical, Inc.
As of Oct 22, 2026, Lifecore Biomedical is in Stage 1, the basing phase, now in week 3 (since Oct 5, 2026). It closed at $6.37, 27.8% below its 52-week high and above its 200-day average, which is falling.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Nether… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is LFCR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
LFCR among Drug Manufacturers - Specialty & Generic33rd of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …33 | LFCR | Stage 1 · wk 3 | 49 | +44.8% |
Lifecore Biomedical: quick answers
What stage is Lifecore Biomedical in?
As of Oct 22, 2026, Lifecore Biomedical (LFCR) is in Stage 1, the basing phase. It entered Stage 1 on Oct 5, 2026 and is in week 3. What the four stages mean
Is Lifecore Biomedical in an uptrend?
Not yet. Lifecore Biomedical is in Stage 1, a base that can come before an uptrend. It trades 14.8% above its 200-day average, which is falling.
How far is Lifecore Biomedical from its 52-week high?
Lifecore Biomedical closed at $6.37 on Oct 22, 2026, 27.8% below its 52-week high of $8.82. Its 52-week low is $3.66.
How has Lifecore Biomedical performed over the past year?
As of Oct 22, 2026, Lifecore Biomedical is down 5.8% over the past year and down 17.7% so far in 2026.
Which sector and industry is Lifecore Biomedical in?
Lifecore Biomedical is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.